Trinity Biotech Achieves Profitability Milestone Amid Strategic Turnaround

An update from Trinity Biotech ( (TRIB) ) is now available.

On July 1, 2025, Trinity Biotech announced it had reached a profitability inflection point, a major milestone in its strategic turnaround. The company reported its financial results for the quarter ended March 31, 2025, and projected a positive Adjusted EBITDA from Q3 2025 onwards. This achievement follows significant operational restructuring, including offshoring manufacturing, which has reduced costs and positioned the company for sustainable profitability. Trinity Biotech is now focusing on expanding its product offerings, including diabetes care and HIV tests, and advancing its pipeline of diagnostic tests, such as preeclampsia and prostate cancer tests. The company also continues to develop its next-generation continuous glucose monitoring solution, aiming to capture a significant share of the growing global market.

Spark’s Take on TRIB Stock

According to Spark, TipRanks’ AI Analyst, TRIB is a Neutral.

Trinity Biotech’s overall stock score is heavily impacted by its weak financial performance, characterized by declining revenues, negative equity, and high debt levels. Technical analysis shows mixed signals with the price slightly below moving averages and neutral momentum indicators, while valuation is poor due to negative earnings and lack of dividends.

To see Spark’s full report on TRIB stock, click here.

More about Trinity Biotech

Trinity Biotech plc is a commercial stage biotechnology company based in Ireland, focusing on human diagnostics and diabetes management solutions, including wearable biosensors.

Average Trading Volume: 819,324

Technical Sentiment Signal: Sell

Current Market Cap: $12.12M

See more data about TRIB stock on TipRanks’ Stock Analysis page.